UB Paderborn / Katalog / Suche / in CDI

Clinical Trial Simulation: A Review

Clinical pharmacology and therapeutics, 2010-08, Vol.88 (2), p.166-182

2010

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-07, Vol.23 (4), p.528-537

2017

Link zum Volltext

Verfügbarkeit prüfen

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Trends in pharmacological sciences (Regular ed.), 2008-04, Vol.29 (4), p.186-191

2008

Link zum Volltext

Verfügbarkeit prüfen

Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences

Scandinavian journal of trauma, resuscitation and emergency medicine, 2021-08, Vol.29 (1), p.128-128, Article 128

2021

Link zum Volltext

Verfügbarkeit prüfen

Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction

Annals of oncology, 2019-07, Vol.30, p.iv90-iv90

2019

Link zum Volltext

Verfügbarkeit prüfen

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

British journal of pharmacology, 2014-11, Vol.171 (22), p.5076-5092

2014

Link zum Volltext

Verfügbarkeit prüfen

Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S204-S205

2017

Link zum Volltext

Verfügbarkeit prüfen

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

British journal of pharmacology, 2013-08, Vol.169 (7), p.1510-1524

2013

Link zum Volltext

Verfügbarkeit prüfen

Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs

Journal of veterinary pharmacology and therapeutics, 2013-04, Vol.36 (2), p.174-180

2013

Link zum Volltext

Verfügbarkeit prüfen

Verification of reactive systems via instantiation of Parameterised Boolean Equation Systems

Information and computation, 2011-04, Vol.209 (4), p.637-663

2011

Link zum Volltext

Verfügbarkeit prüfen

Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations

Toxicology and applied pharmacology, 1999-08, Vol.158 (3), p.261-268

1999

Link zum Volltext

Verfügbarkeit prüfen

Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

European journal of cancer (1990), 2022-10, Vol.174, p.S101-S101

2022

Link zum Volltext

Verfügbarkeit prüfen

Guideline on anterior cruciate ligament injury

Acta orthopaedica, 2012-08, Vol.83 (4), p.379-386

2012

Link zum Volltext

Verfügbarkeit prüfen

Guideline on anterior cruciate ligament injury: A multidisciplinary review by the Dutch Orthopaedic Association

Acta orthopaedica, 2012-08, Vol.83 (4), p.379-386

2012

Link zum Volltext

Verfügbarkeit prüfen

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

The Journal of biological chemistry, 2012-11, Vol.287 (49), p.41245-41257

2012

Link zum Volltext

Verfügbarkeit prüfen

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

Toxicology and applied pharmacology, 2000-02, Vol.162 (3), p.177-188

2000

Link zum Volltext

Verfügbarkeit prüfen

A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat

Journal of pharmacokinetics and pharmacodynamics, 2011-12, Vol.38 (6), p.697-711

2011

Link zum Volltext

Verfügbarkeit prüfen

A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

European urology, 2023-02, Vol.83, p.S1709-S1710

2023

Link zum Volltext

Verfügbarkeit prüfen

Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

European urology, 2023-02, Vol.83, p.S1709-S1710

2023

Link zum Volltext

Verfügbarkeit prüfen

PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin

Clinical pharmacology and therapeutics, 2004-02, Vol.75 (2), p.P80-P80

2004

Link zum Volltext

Verfügbarkeit prüfen

An integrated evaluation of phase 1 data including exposure-response analysis shows vilaprisan does not delay cardiac repolarization

Fertility and sterility, 2018-09, Vol.110 (4), p.e139-e139

2018

Link zum Volltext

Verfügbarkeit prüfen

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Pharmaceutical research, 2000-12, Vol.17 (12), p.1516-1525

2000

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-16-03

2018

Link zum Volltext

Verfügbarkeit prüfen

THU-067 - Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Journal of hepatology, 2017, Vol.66 (1), p.S204-S205

2017

Link zum Volltext

Verfügbarkeit prüfen

Dutch guideline on total hip prosthesis

Acta orthopaedica, 2011-10, Vol.82 (5), p.567-576

2011

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Clinical Trial Simulation: A Review

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences

Exploration of alternative regorafenib regimens to manage hand-foot-skin-reaction

Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling

Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs

Verification of reactive systems via instantiation of Parameterised Boolean Equation Systems

Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations

Optimization of treatment schedule for the ATR inhibitor elimusertib (BAY 1895344) in preclinical tumor models

Guideline on anterior cruciate ligament injury

Guideline on anterior cruciate ligament injury: A multidisciplinary review by the Dutch Orthopaedic Association

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat

A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin

An integrated evaluation of phase 1 data including exposure-response analysis shows vilaprisan does not delay cardiac repolarization

A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling

Abstract P1-16-03: An open-label, multicenter phase 1b trial of radium-223 + paclitaxel in cancer patients with bone metastases: Safety results from the breast cancer patient subgroup

THU-067 - Correlation of efficacy and safety outcomes with regorafenib exposure in patients with hepatocellular carcinoma

Dutch guideline on total hip prosthesis

Suchergebnisse filtern